Rapid Micro Biosystems (NASDAQ:RPID) Posts Earnings Results, Misses Expectations By $0.05 EPS

Rapid Micro Biosystems (NASDAQ:RPID) announced its quarterly earnings results on Thursday. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.05), FiscalAI reports. The company had revenue of $11.28 million during the quarter, compared to the consensus estimate of $10.93 million. Rapid Micro Biosystems had a negative net margin of 145.11% and a negative return on equity of 73.90%.

Here are the key takeaways from Rapid Micro Biosystems’ conference call:

• Rapid Micro reported a record Q4 with $11.3 million revenue (up 37% YoY) and placed 16 Growth Direct systems in the quarter, finishing 2025 with 190 systems placed (155 fully validated).
• Management set 2026 guidance of $37–$41 million revenue and 30–38 system placements, targeting approximately 20% full‑year gross margin with a Q4 exit in the mid‑20s%, signaling expected margin expansion and growth cadence.
• Q4 product margin was weighed down by a $1.1 million write‑off of unusable consumable inventory, producing a negative overall gross margin for the quarter and contributing to a Q4 net loss of $12.5 million.
• The MilliporeSigma collaboration is progressing (customer demo labs in Europe and Asia) and management says recent procurement agreements and supply‑chain actions will drive meaningful consumable cost reductions that should accelerate gross‑margin improvement in H2 2026.
• Rapid Micro plans a next‑generation cloud‑native software platform with AI analytics in H2 2026 to enable fleet‑level insights and potential higher‑margin services, but monetization timing and scale remain uncertain.

Rapid Micro Biosystems Trading Down 21.9%

Shares of Rapid Micro Biosystems stock opened at $3.42 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 4.23 and a quick ratio of 2.95. The stock has a market cap of $151.58 million, a P/E ratio of -3.39 and a beta of 1.38. The stock’s 50 day simple moving average is $3.98 and its 200-day simple moving average is $3.54. Rapid Micro Biosystems has a 1-year low of $1.86 and a 1-year high of $4.94.

Key Stories Impacting Rapid Micro Biosystems

Here are the key news stories impacting Rapid Micro Biosystems this week:

• Positive Sentiment: Reported record 2025 results and raised outlook — Rapid Micro reported record Q4 and full‑year 2025 revenue (Q4 $11.3M; FY $33.6M), and gave 2026 revenue guidance of $37.0M–$41.0M and 30–38 Growth Direct system placements (gross margin ~20%). This confirms accelerating commercial adoption. MSN: Record 2025 performance
• Positive Sentiment: Follow‑on multi‑system orders from large CDMOs — Rapid Micro announced meaningful multi‑system follow‑on orders from Samsung Biologics and noted Amgen expanded its Growth Direct rollout, signaling strong enterprise demand from major contract manufacturers. These orders accelerate recurring revenue and reference‑customer validation. GlobeNewswire: Samsung multi-system order
• Neutral Sentiment: Guidance roughly in line with consensus — FY‑2026 revenue range ($37–$41M) brackets the consensus (~$39.7M). That leaves upside tied to the pace and size of system placements and service/consumable attach rates. GlobeNewswire: FY 2026 guidance
• Neutral Sentiment: Earnings call emphasized growth vs. near‑term margin/operating pressure — Management reiterated commercial momentum but flagged execution and margin items that could keep volatility in results; read the call highlights for detail on sales cadence and cost assumptions. TipRanks: Earnings call highlights
• Negative Sentiment: Q4 EPS missed while revenue slightly beat — Rapid Micro reported EPS of ($0.28) vs. consensus ($0.23) miss, despite revenue of $11.28M beating estimates. Continued negative margins and ROE highlight that growth has not yet translated to profitability. MarketBeat: Q4 results
• Negative Sentiment: Insider selling by CEO, CFO and COO — Recent Form 4 filings show the CEO, CFO and COO sold shares (combined modest percentages of their holdings). While not necessarily a red flag for a founder‑led company, clustered insider sales can weigh on sentiment for a small‑cap name. SEC: CEO Form 4 (example)

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on RPID shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research note on Thursday, January 22nd. Wall Street Zen upgraded Rapid Micro Biosystems from a “sell” rating to a “hold” rating in a report on Saturday, February 14th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $8.00.

Insider Activity at Rapid Micro Biosystems

In other Rapid Micro Biosystems news, COO John J. Addington Wilson sold 9,603 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $4.32, for a total transaction of $41,484.96. Following the completion of the sale, the chief operating officer directly owned 316,762 shares in the company, valued at $1,368,411.84. The trade was a 2.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Sean M. Wirtjes sold 7,480 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $4.32, for a total transaction of $32,313.60. Following the completion of the transaction, the chief financial officer owned 556,194 shares in the company, valued at approximately $2,402,758.08. The trade was a 1.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 249,705 shares of company stock valued at $1,021,364 in the last ninety days. 29.96% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Rapid Micro Biosystems

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in Rapid Micro Biosystems by 6.7% during the 3rd quarter. Vanguard Group Inc. now owns 965,018 shares of the company’s stock worth $3,223,000 after purchasing an additional 60,655 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Rapid Micro Biosystems by 6.3% in the fourth quarter. Geode Capital Management LLC now owns 217,568 shares of the company’s stock worth $631,000 after buying an additional 12,881 shares during the period. 683 Capital Management LLC bought a new position in Rapid Micro Biosystems in the 4th quarter worth about $350,000. Millennium Management LLC purchased a new position in shares of Rapid Micro Biosystems in the 4th quarter worth $338,000. Finally, Renaissance Technologies LLC boosted its position in shares of Rapid Micro Biosystems by 4.9% in the fourth quarter. Renaissance Technologies LLC now owns 115,627 shares of the company’s stock worth $335,000 after purchasing an additional 5,440 shares during the period. Institutional investors and hedge funds own 52.60% of the company’s stock.

Rapid Micro Biosystems Company Profile

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.